1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Procter & Gamble Health Ltd.

Procter & Gamble Health Ltd.

5,015.00
INR
-47.50
(-0.94%)
215.19EPS
29.40P/E
105.02BMarket Cap
Dec 02Next Earn
Procter & Gamble Health Ltd.
NSE:PGHL
(National Stock Exchange of India)

Recent

price

5,015.00

P/E

ratio

29.40

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2026
TTM
INR
282.1
306.69
333.52
413.05
478.31
519.84
564.82
597.95
420.58
492.9
558.21
596.88
657.88
726.45
680.44
834.44
864.03
Revenue per Share
39.04
38.06
38.36
47.23
33.66
26.04
32.27
47.67
56.57
505.27
95.64
106.51
115.98
138.24
121.08
196.94
215.19
Basic EPS, GAAP
19.19
34.45
2.25
24.49
-19.86
-21.34
23.06
45.42
14.07
-94.65
91.12
117.28
79.28
116.58
124.44
194.15
- -
Free Cash Flow per Basic Share
17.57
114.43
- -
- -
2.5
8.57
5.98
7.5
11
15.04
439.31
230
171
56.5
250
205
- -
Dividend per Share
281.51
208.69
247.05
291.37
315.09
333.93
362.06
399.91
441.74
927.81
492.07
423.94
371.39
452.36
324.25
316.01
- -
Book Value per Share
281.51
208.69
246.9
291.29
314.93
333.81
361.97
399.8
441.26
927.55
491.87
423.87
371.37
451.79
323.67
315.72
- -
Tangible Book Value per Share
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
Basic Weighted Avg Shares
4,731
5,091
5,536
6,856
7,940
8,629
9,376
9,926
6,981
8,182
9,266
9,908
10,920
12,059
11,295
13,851
14,329
Sales/Revenue/Turnover
20.39
18.81
16.12
14.17
8.57
5.4
10.59
13.3
18.52
15.62
20.12
22.72
22.69
24.53
24.71
31.4
30.83
Operating Margin (%)
75
71
80
89
101
127
234
248
264
250
172
300
271
281
274
236
242
Depreciation Expense
655
632
637
784
559
432
536
791
939
8,387
1,588
1,768
1,925
2,295
2,010
3,269
3,569
Net Income, GAAP
32.11
33.99
33.38
32.87
36.68
35.07
35.73
31.3
38.27
35.6
32.26
24.21
24.02
26.97
26.47
27.33
27.19
Effective Tax Rate (%)
13.84
12.41
11.5
11.43
7.04
5.01
5.71
7.97
13.45
102.51
17.13
17.84
17.63
19.03
17.79
23.6
24.91
Profit Margin (%)
3,816
2,715
3,029
3,614
3,658
3,634
4,140
4,497
5,271
13,415
6,229
4,882
3,761
4,922
3,053
3,013
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
29
- -
89
69
57
- -
LT Debt
4,673
3,464
4,101
4,837
5,230
5,543
6,010
6,638
7,333
15,401
8,168
7,037
6,165
7,509
5,382
5,246
- -
Total Equity
14.26
15.54
18.27
14.52
8.34
5.51
10.87
13.36
10.64
7.39
10.39
21.26
27.08
30.89
28.6
56.8
- -
Return on Invested Capital (%)
14.26
15.54
16.84
17.54
11.1
8.02
9.25
12.4
13.3
73.36
13.43
23.22
28.98
33.28
30.75
60.52
- -
Return on Capital (%)
14.26
15.53
16.84
17.54
11.1
8.02
9.27
12.51
13.44
73.79
13.47
23.26
29.17
33.56
31.18
61.52
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
36
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
57
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
94,666
79,657
105,023

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
5,563
- -
Cash, Cash Equivalents & STI
- -
2,015
- -
Accounts Receivable, Net
- -
1,643
- -
Inventories
- -
1,367
- -
Total Current Liabilities
- -
2,549
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
36
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
-7.06%
-2.54%
Free Cash Flow
-104.28%
21.23%
56.02%
Net Income, GAAP
89.21%
17.94%
62.66%
Sales/Revenue/Turnover
5.92%
8.77%
22.63%
Total Cash Common Dividend
308.33%
36.84%
-18%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2026
3,387
3,249
3,739
3,705
13,851
2027
3,637
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2026
39.87
53.54
46.74
56.99
196.94
2027
57.92
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2026
- -
- -
- -
- -
205
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Procter & Gamble Health Limited manufactures and markets over-the-counter healthcare products, vitamins, minerals, and supplements in India; its core brands include Evion (Vitamin E), Neurobion (Vitamin B-complex for nerve health), Polybion (Vitamin B-complex), Seven Seas (cod liver oil supplements), Nasivion (nasal decongestants), Livogen (iron supplements for anemia), and Cosome (cough relief); the company operates a GMP-certified manufacturing facility in Usgaon, Goa, with capacity for over 260 million ampoules and 744 million softgel capsules annually, exporting to 13 countries. Founded in 1967 as a Merck subsidiary and headquartered in Mumbai, India, it changed its name from Merck Limited to Procter & Gamble Health Limited in May 2019 following P&G's acquisition of Merck's Consumer Health business in December 2018, with Procter & Gamble Overseas India B.V. holding 51.81% ownership. The company primarily serves consumers through distributors, pharmacies, chemists, and healthcare professionals in India, with additional exports to Sri Lanka, Nepal, Myanmar, and Maldives. Recent developments include revised maximum retail prices effective September 22, 2025, due to GST rate changes; strong Q2 fiscal 2026 results with sales of Rs 319 crore (up 3% YoY) and profit after tax of Rs 89 crore (up 8% YoY) as of September 30, 2025; and shareholder approval in November 2025 for appointing Shashank Srowthy as an Executive Director.